NEW YORK (GenomeWeb News) – Pharmacogenetic diagnostic developer TheraGenetics said today that it has licensed intellectual property from the Centre for Addiction and Mental Health in Ontario, Canada, related to predicting patient response to antidepressants.
 
TheraGenetics, which is developing a suite of tests to guide the treatment of central nervous system disorders, said that the kits will help determine whether certain patients are susceptible to side-effects from antidepressants.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.